Table I.

Patient Characteristics by Treatment Group. Data presented as median (25^th – 75^th percentile).

	n	Non-HCT n= 52	HCT n= 26	p-value*
Age (years) at study visit	78	14.5 (11.6 – 16.7)	15.6 (12.5 – 17.2)	0.47
Gender (% male)	78	48% (25)	62% (16)	0.38
Race (% Caucasian)	78	81% (42)	69% (18)	0.39
Years since Diagnosis	78	10.0 (6.8 – 11.2)	10.5 (6.2 – 12.0)	0.88
Received CRT	78	12% (6)	39 % (10)	0.01
Received TBI	78	0% (0)	100% (26)	NA
Diagnosis of growth hormone deficiency	27	4% (2)	50% (13)	0.78
Hypothyroidism	27	6% (3)	23% (6)	0.38
HOMA	77	1.4 (0.9 – 2.0)	2.6 (1.5 – 3.7)	0.01
Height z-score	70	0.15 (-0.53 – 1.10)	-0.44 (-1.28 – 0.02)	0.02
Weight z-score	70	0.77 (0.12 – 1.45)	0.68 (-0.50 – 1.56)	0.47
BMI z-score	74	0.70 (0.14 – 1.43)	0.83 (-0.24 – 1.62)	0.94
UV 30 **	78	5.4 (2.5 – 6.9)	3.9 (1.4 – 4.9)	0.02
Dietary vitamin D intake/ day (IU)***	76	283 (171 – 409)	177 (108 – 321)	0.05
% meeting RDA for vitamin D intake	76	27% (14)	8% (2)	0.08
Calcium intake/ day (mg)**	76	1145 (809 – 1698)	948 (622 – 1336)	0.11
% meeting RDA for calcium intake	76	42% (22)	31% (8)	0.38
% receiving vitamin D supplements	76	19% (10)	35% (9)	0.20

^*For continuous variables the Wilcoxon rank sum test, for categorical variables the Pearson chi-squared test;

^**UV30: a measurement of the average amount of UV light in the patient's geographic location during the 30 days prior to the serum vitamin D evaluation;

^***Reported dietary intake, not including supplement use